Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Vaccines

Free Subscription 08.04.2024 1 Arch Virol 1 BMC Pediatr 2 BMJ 2 Clin Infect Dis 3 J Infect 1 J Infect Dis 1 J Pediatr 3 J Virol 1 JAMA 2 Lancet 2 MMWR Morb Mortal Wkly Rep 1 Nat Med 9 PLoS One 11 Vaccine

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Arch Virol

1. ALVAREZ-QUINTO R, Grinstead S, Kinard G, Martin R, et al
   Complete genome sequence of vaccinium-associated virus C, a new member of the family Totiviridae from Vaccinium floribundum.
   Arch Virol. 2024;169:86.
   PubMed         Abstract available
   
   

   
   BMC Pediatr

2. KAMALI M, Navaeifar MR, Abbaskhanian A, Hajialibeig A, et al
   Unusual presentation of miliary tuberculosis in a 12-year-old girl: a case report.
   BMC Pediatr. 2024;24:223.
   PubMed         Abstract available
   
   

   
   BMJ

3. DE OLIVEIRA ANDRADE R
   After years of decline, Brazil sees vaccination coverage rise in 2023.
   BMJ. 2024;385:q668.
   PubMed        
   
   
4. MAHASE E
   Measles: South Sudan reports 12 000 cases in three months.
   BMJ. 2024;384:q777.
   PubMed        
   
   

   
   Clin Infect Dis

5. FAHERTY EAG, Holly T, Ogale YP, Spencer H, et al
   Investigation of an mpox outbreak affecting many vaccinated persons in Chicago, IL-March 2023-June 2023.
   Clin Infect Dis. 2024 Apr 3:ciae181. doi: 10.1093.
   PubMed         Abstract available
   
   
6. SU WJ, Chen HL, Chen SF, Liu YL, et al
   Optimization of Mother-to-Child Hepatitis B Virus Prevention Program: Integration of Maternal Screening and Infant Post-vaccination Serologic Testing.
   Clin Infect Dis. 2024 Apr 2:ciae176. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Infect

7. NG M, S D, L W, R B, et al
   Paediatric meningitis in the conjugate vaccine era and a novel clinical decision model to predict bacterial aetiology.
   J Infect. 2024 Mar 27:106145. doi: 10.1016/j.jinf.2024.106145.
   PubMed         Abstract available
   
   
8. MENGYANG G, Yahong H, Qinghong M, Wei S, et al
   Resurgence and atypical patterns of pertussis in China.
   J Infect. 2024;88:106140.
   PubMed        
   
   
9. MEERAUS W, Joy M, Ouwens M, Taylor KS, et al
   AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: the RAVEN cohort study.
   J Infect. 2024 Feb 29:106129. doi: 10.1016/j.jinf.2024.106129.
   PubMed         Abstract available
   
   

   
   J Infect Dis

10. TAIT D, Diacon A, Borges AH, van Brakel E, et al
    Safety and immunogenicity of the H56:IC31 tuberculosis vaccine candidate in adults successfully treated for drug-susceptible pulmonary TB: a phase 1 randomized trial.
    J Infect Dis. 2024 Apr 1:jiae170. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Pediatr

11. CLOPPER BR, Zhou Y, Tannis A, Staat MA, et al
    Medical Costs of RSV-associated Hospitalizations and Emergency Department Visits in Children Aged <5 years: Observational Findings from the New Vaccine Surveillance Network (NVSN), 2016-2019.
    J Pediatr. 2024 Mar 30:114045. doi: 10.1016/j.jpeds.2024.114045.
    PubMed         Abstract available
    
    

    
    J Virol

12. MANTEL N, Piras-Douce F, Chautard E, Marcos-Lopez E, et al
    Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.
    J Virol. 2024 Apr 3:e0151623. doi: 10.1128/jvi.01516.
    PubMed         Abstract available
    
    
13. BRUNET J, Choucha Z, Gransagne M, Tabbal H, et al
    A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
    J Virol. 2024 Apr 2:e0169323. doi: 10.1128/jvi.01693.
    PubMed         Abstract available
    
    
14. NAMBULLI S, Escriou N, Rennick LJ, Demers MJ, et al
    A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
    J Virol. 2024 Apr 2:e0176223. doi: 10.1128/jvi.01762.
    PubMed         Abstract available
    
    

    
    JAMA

15. ANDERER S
    CDC Recommends Additional COVID-19 Booster for Older Adults.
    JAMA. 2024 Mar 13. doi: 10.1001/jama.2024.2071.
    PubMed        
    
    

    
    Lancet

16. RAQIB R
    Bivalent conjugate vaccines for typhoid and paratyphoid fever.
    Lancet. 2024 Mar 28:S0140-6736(24)00461-6. doi: 10.1016/S0140-6736(24)00461.
    PubMed        
    
    
17. KULKARNI PS, Potey AV, Bharati S, Kunhihitlu A, et al
    The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
    Lancet. 2024 Mar 28:S0140-6736(24)00249-6. doi: 10.1016/S0140-6736(24)00249.
    PubMed         Abstract available
    
    

    
    MMWR Morb Mortal Wkly Rep

18. EL KALACH R, Jones-Jack N, Elam MA, Olorukooba A, et al
    Federal Retail Pharmacy Program Contributions to Bivalent mRNA COVID-19 Vaccinations Across Sociodemographic Characteristics - United States, September 1, 2022-September 30, 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:286-290.
    PubMed         Abstract available
    
    
19. THOMAS CM, Hartley A, Schmitz A, Reid HD, et al
    Implications of Measles Inclusion by Commercial Syndromic Polymerase Chain Reaction Panels - United States, May 2022-April 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:260-264.
    PubMed         Abstract available
    
    

    
    Nat Med

20. 
    Systematic testing in cholera surveillance enhances vaccine impact and cost-effectiveness.
    Nat Med. 2024 Apr 3. doi: 10.1038/s41591-024-02907.
    PubMed        
    
    

    
    PLoS One

21. THANGARAJ JWV, Prosperi C, Kumar MS, Hasan AZ, et al
    Post-campaign coverage evaluation of a measles and rubella supplementary immunization activity in five districts in India, 2019-2020.
    PLoS One. 2024;19:e0297385.
    PubMed         Abstract available
    
    
22. RICCI CONESA H, Skroder H, Norton N, Bencina G, et al
    Clinical and economic burden of acute otitis media caused by Streptococcus pneumoniae in European children, after widespread use of PCVs-A systematic literature review of published evidence.
    PLoS One. 2024;19:e0297098.
    PubMed         Abstract available
    
    
23. ECHEVERRI TRIBIN F, Williams E, Testamarck V, Carreno JM, et al
    Determinants of health as predictors for differential antibody responses following SARS-CoV-2 primary and booster vaccination in an at-risk, longitudinal cohort.
    PLoS One. 2024;19:e0292566.
    PubMed         Abstract available
    
    
24. MWANGI LW, Omuse G, Adam R, Ong'ete G, et al
    Post-vaccination SARS-CoV-2 IgG spike antibody responses among clinical and non-clinical healthcare workers at a tertiary facility in Kenya.
    PLoS One. 2024;19:e0299302.
    PubMed         Abstract available
    
    
25. HERNANDEZ-BELLO J, Lorenzo-Leal AC, Munoz-Valle JF, Morales-Nunez JJ, et al
    Neutralizing antibody responses to the Delta variant of SARS-CoV-2 following vaccination with Ad5-nCoV (CanSino) in the Mexican population.
    PLoS One. 2024;19:e0299520.
    PubMed         Abstract available
    
    
26. SILVA LA, Souza MF, Carvalho TP, Santana CH, et al
    Comparative study on alginate/chitosan microcapsules and Montanide ISA 61 as vaccine adjuvants in mice.
    PLoS One. 2024;19:e0298117.
    PubMed         Abstract available
    
    
27. FISMAN DN, Amoako A, Simmons A, Tuite AR, et al
    Impact of immune evasion, waning and boosting on dynamics of population mixing between a vaccinated majority and unvaccinated minority.
    PLoS One. 2024;19:e0297093.
    PubMed         Abstract available
    
    
28. AGIMAS MC, Belew AK, Sisay M, Daniel Baffa L, et al
    Spatial variations and determinants of timely completion of vaccination in Ethiopia using further analysis of EDHS 2019 data: Spatial and multilevel analysis.
    PLoS One. 2024;19:e0301409.
    PubMed         Abstract available
    
    
29. THERESA POOL SN, Shroff EH, Chetty A, Lewis L, et al
    Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against COVID-19-associated hospitalisation and death in the Seychelles infected adult population.
    PLoS One. 2024;19:e0299747.
    PubMed         Abstract available
    
    

    
    Vaccine

30. PADENIYA TN, Hui BB, Wood JG, Regan DG, et al
    Review of mathematical models of Neisseria gonorrhoeae vaccine impact: Implications for vaccine development.
    Vaccine. 2024 Mar 30:S0264-410X(24)00380-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
31. HUF SW, Grailey K, Crespo RF, Woldmann L, et al
    Testing the impact of differing behavioural science informed text message content in COVID-19 vaccination invitations on vaccine uptake: A randomised clinical trial.
    Vaccine. 2024 Mar 28:S0264-410X(24)00365-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
32. MALTEZOU HC, Kontogianni S, Michailidou E, Vergadi E, et al
    Effectiveness of COVID-19 vaccination against school absenteeism in children and adolescents hospitalized with COVID-19.
    Vaccine. 2024 Mar 30:S0264-410X(24)00397-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
33. GONG JD, Barnboym E, O'Mara M, Gurevich N, et al
    Self-reported determinants of COVID-19 vaccine acceptance among persons with and without autoimmune disease.
    Vaccine. 2024 Mar 30:S0264-410X(24)00373-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
34. KIMBUGWE G, Vatrinet R, Mwanga JA, Kakuru R, et al
    Perceptions, attitudes, and willingness of healthcare and frontline workers to participate in an Ebola vaccine trial in Uganda.
    Vaccine. 2024 Apr 1:S0264-410X(24)00358-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
35. TEMBO G, Mayuni M, Kamng'ona R, Chimgoneko L, et al
    Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation.
    Vaccine. 2024 Apr 2:S0264-410X(24)00360-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
36. NURDIN A, Movieta Nency Y, Maddeppungeng M, Sekartini R, et al
    Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial.
    Vaccine. 2024 Apr 3:S0264-410X(24)00399-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
37. HEISLER-MACKINNON JA, Queen T, Yi Kong W, Kennedy KL, et al
    Identifying effective vaccine champions: Findings from a national survey of primary care professionals.
    Vaccine. 2024 Apr 3:S0264-410X(24)00403-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
38. ALTAWALBEH SM, Wateska AR, Nowalk MP, Lin CJ, et al
    Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older.
    Vaccine. 2024 Apr 4:S0264-410X(24)00404-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
39. BAUM HE, Thirard R, Halliday A, Baos S, et al
    Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial.
    Vaccine. 2024 Apr 4:S0264-410X(24)00367-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
40. SCHULTZE A, Martin I, Messina D, Bots S, et al
    A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases.
    Vaccine. 2024 Apr 5:S0264-410X(24)00330-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.